Organic Chemical – Page 37

Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer

1 year ago talkbio0Tagged CDK4/6 inhibitor, ESR1 gene, Estrogen receptor positive, HER2-, Imlunestrant, Malignant neoplasm of breast, Mutation, Oral SERD, Progression-Free Survival, Verzenio

Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor

Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks

1 year ago talkbio0Tagged Acelyrin, Arthritis, Psoriatic, biotech, Clinical Trials, Failure (biologic function), Hidradenitis, Immunology, IPO, Izokibep, suppurativa

Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO

Walgreens Boots Alliance in Negotiations for Potential Sale to Private Equity Firm Sycamore Partners

1 year ago talkbio0Tagged Boots Alliance, Health care facility, Industry, Partner in relationship, Platanus occidentalis whole extract, private equity sale, Walgreens

Walgreens Boots Alliance, Sycamore Partners, private equity sale, retail industry, healthcare retail

Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial

1 year ago talkbio0Tagged Cardiff Oncology, first-line, onvansertib, ORR, Phase 2, RAS, RAS-mutated

Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

1 year ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial

1 year ago talkbio0Tagged Clinical Trials, Keytruda, Lynparza, ovarian neoplasm, Progression-Free Survival, Survival

Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival

Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy

1 year ago talkbio0Tagged Citryll, Forbion, Inflammatory Disease Therapy, Johnson & Johnson Innovation, Neutrophil Extracellular Traps, Novartis, Series B, venture fund

Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion